AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10355866 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin treatment after placebo for long-term
Number of subjects: 31
Study 7486296 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) transfusion
Number of subjects: 20
Study 7486296 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PRP transfusion)
Number of subjects: 20
Study 1778534 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% halometasone cream
Number of subjects: 165
Study 1778534 — intervention group
Group type: COMPARATOR
Intervention: 0.25% prednicarbate cream
Number of subjects: 165
Study 6183898 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral D-penicillamine
Number of subjects: 9
Study 6183898 — intervention group
Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 9
Study 31384071 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-led total sanitation campaign (2006)
Number of subjects: 1000
Study 31384071 — intervention group
Group type: COMPARATOR
Intervention: Control villages
Number of subjects: 1000
Study 29782224 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab (300 mg every 2 weeks for 24 weeks)
Number of subjects: 210
Study 29782224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 29782224 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 210
Study 27216328 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cognitive‐behavioural group interventions (Baghira group training and Positive Parenting Program Triple P)
Number of subjects: 42
Study 27216328 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 42
Study 24581894 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortened form of problem-solving therapy focusing on caregiver burden
Number of subjects: 140
Study 24581894 — intervention group
Group type: COMPARATOR
Intervention: Educational intervention focusing on respiratory diseases (Control Group)
Number of subjects: 140
Study 22149151 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release aceclofenac 200 mg od (Clanza CR®)
Number of subjects: 41
Study 22149151 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release aceclofenac 100 mg bid (Airtal®)
Number of subjects: 41
Study 22149151 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release aceclofenac 200 mg od (Clanza CR®) fed state
Number of subjects: 41
Study 22149151 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release aceclofenac 200 mg od (Clanza CR®) fasted state
Number of subjects: 41
Study 20228982 — intervention group
Group type: EXPERIMENTAL
Intervention: Core Max II without total-etch adhesive
Number of subjects: 60
Study 20228982 — intervention group
Group type: EXPERIMENTAL
Intervention: Core Max II with total-etch adhesive
Number of subjects: 60
Study 20228982 — intervention group
Group type: EXPERIMENTAL
Intervention: Panavia F2.0 cement without self-etch adhesive
Number of subjects: 60
Study 20228982 — intervention group
Group type: EXPERIMENTAL
Intervention: Panavia F2.0 cement with self-etch adhesive
Number of subjects: 60
Study 20228982 — intervention group
Group type: EXPERIMENTAL
Intervention: Core Max II with adhesive
Number of subjects: 60
Study 20228982 — intervention group
Group type: COMPARATOR
Intervention: Core Max II without adhesive
Number of subjects: 60
Study 20228982 — intervention group
Group type: EXPERIMENTAL
Intervention: Panavia F2.0 with adhesive
Number of subjects: 60
Study 17137844 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 102
Study 17137844 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical treatment
Number of subjects: 102
Study 16039293 — intervention group
Group type: EXPERIMENTAL
Intervention: 17beta-estradiol 1mg daily
Number of subjects: 180
Study 11966505 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosapride 5 mg b.d.
Number of subjects: 566
Study 11966505 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosapride 10 mg b.d.
Number of subjects: 566
Study 11966505 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosapride 7.5 mg t.d.s.
Number of subjects: 566
Study 11966505 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 566
Study 9603592 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled hypotension with mild hemodilution (Group A)
Number of subjects: 30
Study 9603592 — intervention group
Group type: COMPARATOR
Intervention: Controlled hypotension with moderate hemodilution (Group B)
Number of subjects: 30
Study 8065590 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate (3.75 mg/monthly)
Number of subjects: 50
Study 8065590 — intervention group
Group type: COMPARATOR
Intervention: Danazol (600 mg/daily)
Number of subjects: 50
Study 2967780 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine (4 mg three times daily)
Number of subjects: 112
Study 2967780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 31628887 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient counselling covering asthma knowledge, control, adherence to treatment and inhalation techniques
Number of subjects: 192
Study 29342210 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory of Mind Performance Training (ToMPT)
Number of subjects: 49
Study 29342210 — intervention group
Group type: COMPARATOR
Intervention: Social Skills Training (SST)
Number of subjects: 49
Study 26661992 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot water immersion (HWI) at 40 °C for 40 min after exercise
Number of subjects: 17
Study 26661992 — intervention group
Group type: COMPARATOR
Intervention: Thermoneutral immersion (CON) at 34 °C for 40 min after exercise
Number of subjects: 17
Study 25300460 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilvadipine (8 mg overencapsulated, sustained release capsule)
Number of subjects: 500
Study 25300460 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching overencapsulated sugar pill)
Number of subjects: 500
Study 25300460 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilvadipine
Number of subjects: 500
Study 25300460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study 22791756 — intervention group
Group type: EXPERIMENTAL
Intervention: T gel 10 g + NES gel 8 mg
Number of subjects: 99
Study 22791756 — intervention group
Group type: EXPERIMENTAL
Intervention: T gel 10 g + NES gel 12 mg
Number of subjects: 99
Study 22791756 — intervention group
Group type: COMPARATOR
Intervention: T gel 10 g + NES 0 mg (placebo)
Number of subjects: 99
Study 20406959 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid-organ transplantation
Number of subjects: 83016
Study 18195264 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI measures (ventricular volumes)
Number of subjects: 129
Study 18195264 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI measures (hippocampal volumes)
Number of subjects: 129
Study 18195264 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical variables (including Delayed 10‐word list recall, New York University Delayed Paragraph Recall, Alzheimer's Disease Assessment Scale‐Cognitive Subscale total score)
Number of subjects: 129
Study 18195264 — intervention group
Group type: COMPARATOR
Intervention: Cognitive measures alone
Number of subjects: 129
Study 15647077 — intervention group
Group type: EXPERIMENTAL
Intervention: gamolenic acid (GLA) and antioxidants
Number of subjects: 555
Study 15647077 — intervention group
Group type: COMPARATOR
Intervention: placebo fatty acids and antioxidants
Number of subjects: 555
Study 15647077 — intervention group
Group type: EXPERIMENTAL
Intervention: GLA and placebo antioxidants
Number of subjects: 555
Study 15647077 — intervention group
Group type: COMPARATOR
Intervention: placebo fatty acids and placebo antioxidants
Number of subjects: 555
Study 15029131 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol (5 mg/day)
Number of subjects: 62
Study 15029131 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 62
Study 10943754 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric shoulder strength training
Number of subjects: 69
Study 10943754 — intervention group
Group type: COMPARATOR
Intervention: Isometric shoulder endurance training
Number of subjects: 69
Study 9028785 — intervention group
Group type: EXPERIMENTAL
Intervention: Vision condition
Number of subjects: 3
Study 9028785 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonvision condition
Number of subjects: 3
Study 9028785 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-process, random-walk model
Number of subjects: 3
Study 9028785 — intervention group
Group type: EXPERIMENTAL
Intervention: Ornstein-Uhlenbeck model
Number of subjects: 3
Study 8498757 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ligation
Number of subjects: 77
Study 8498757 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic sclerotherapy
Number of subjects: 77
Study 3088641 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine chewing gum during the withdrawal period
Number of subjects: 25
Study 3088641 — intervention group
Group type: COMPARATOR
Intervention: No nicotine replacement
Number of subjects: 25
Study 2519530 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (60 mg per day, tapered to 20 mg per day)
Number of subjects: 36
Study 2519530 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (7.5 mg per kilogram of body weight per day)
Number of subjects: 36
Study 2519530 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cyclosporine and low dose prednisone
Number of subjects: 36
Study 31727538 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate 1000 mg orally once daily plus prednisone 5 mg orally twice daily until PSA progression followed by enzalutamide 160 mg orally once daily (group A)
Number of subjects: 202
Study 31727538 — intervention group
Group type: COMPARATOR
Intervention: Enzalutamide 160 mg orally once daily (as second-line therapy after abiraterone)
Number of subjects: 202
Study 31727538 — intervention group
Group type: COMPARATOR
Intervention: Abiraterone acetate 1000 mg orally once daily plus prednisone 5 mg orally twice daily (as second-line therapy after enzalutamide)
Number of subjects: 202
Study 28000425 — intervention group
Group type: EXPERIMENTAL
Intervention: Active procedure (pose™ procedure)
Number of subjects: 332
Study 28000425 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 332
Study 25802954 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation at 10 Hz
Number of subjects: 15
Study 25802954 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation at 80 Hz
Number of subjects: 15
Study 25802954 — intervention group
Group type: COMPARATOR
Intervention: Sham (presence of electrodes without stimulation)
Number of subjects: 15
Study 25802954 — intervention group
Group type: COMPARATOR
Intervention: Control (no electrodes)
Number of subjects: 15
Study 23339811 — intervention group
Group type: EXPERIMENTAL
Intervention: XIENCE V everolimus‐eluting stent (EES)
Number of subjects: 300
Study 23339811 — intervention group
Group type: COMPARATOR
Intervention: TAXUS paclitaxel‐eluting stent (PES)
Number of subjects: 300
Study 21606834 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress-shielding polymer
Number of subjects: 9
Study 21606834 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 9
Study 21606834 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress shielding of swine incisions
Number of subjects: 9
Study 21606834 — intervention group
Group type: COMPARATOR
Intervention: Control and elevated stress states
Number of subjects: 9
Study 19917955 — intervention group
Group type: EXPERIMENTAL
Intervention: Alefacept for 12 consecutive weeks
Number of subjects: 45
Study 19917955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 16697728 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal splenorenal shunt (DSRS)
Number of subjects: 140
Study 16697728 — intervention group
Group type: COMPARATOR
Intervention: Transjugular intrahepatic portal systemic shunt (TIPS)
Number of subjects: 140
Study 15725969 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.3 mg/kg
Number of subjects: 36
Study 15725969 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.6 mg/kg
Number of subjects: 36
Study 15725969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 11159149 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 0
Study 11159149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9424900 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple therapy
Number of subjects: 0
Study 7951706 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-day casting period
Number of subjects: 15
Study 7951706 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day casting period
Number of subjects: 15
Study 2439457 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% dextran 40 (n = 8)
Number of subjects: 18
Study 2439457 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% hydroxyethyl starch 200/0.5 (n = 10)
Number of subjects: 18
Study 29661195 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline development group with patient representatives
Number of subjects: 0
Study 29661195 — intervention group
Group type: COMPARATOR
Intervention: Guideline development group without patient representatives
Number of subjects: 0
Study 28439352 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative practice with instructor feedback (PPF)
Number of subjects: 18
Study 28439352 — intervention group
Group type: COMPARATOR
Intervention: Preoperative practice alone (PP)
Number of subjects: 18
Study 28439352 — intervention group
Group type: COMPARATOR
Intervention: Feedback alone (F)
Number of subjects: 18
Study 26254706 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta2-microglobulin >1.92 mg/L
Number of subjects: 697
Study 26254706 — intervention group
Group type: EXPERIMENTAL
Intervention: C-peptide <1.32 ng/ml
Number of subjects: 697
Study 26254706 — intervention group
Group type: EXPERIMENTAL
Intervention: C-peptide <2.22 ng/ml
Number of subjects: 697
Study 26254706 — intervention group
Group type: EXPERIMENTAL
Intervention: High-density lipoprotein (HDL)
Number of subjects: 697
Study 26254706 — intervention group
Group type: EXPERIMENTAL
Intervention: Transferrin
Number of subjects: 697
Study 26254706 — intervention group
Group type: EXPERIMENTAL
Intervention: History of angina pectoris
Number of subjects: 697
Study 26254706 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL
Number of subjects: 697
Study 23714781 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilpivirine (RPV)
Number of subjects: 1368
Study 23714781 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz (EFV)
Number of subjects: 1368
Study 21395656 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg twice daily
Number of subjects: 19
Study 21395656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 19033149 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (CBT)
Number of subjects: 263
Study 19033149 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based problem solving therapy (PST)
Number of subjects: 263
Study 19033149 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control (WL)
Number of subjects: 263
Study 17153820 — intervention group
Group type: EXPERIMENTAL
Intervention: Priority mail
Number of subjects: 260
Study 17153820 — intervention group
Group type: COMPARATOR
Intervention: First-Class mail
Number of subjects: 260
Study 14610160 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 14703
Study 14610160 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan plus captopril
Number of subjects: 14703
Study 14610160 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 14703
Study 14610160 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan and captopril
Number of subjects: 14703
Study 10705068 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based asthma health education session
Number of subjects: 40
Study 10705068 — intervention group
Group type: COMPARATOR
Intervention: Booklet representing conventional care
Number of subjects: 40
Study 8856613 — intervention group
Group type: EXPERIMENTAL
Intervention: V beta 17 peptide vaccination (10, 30, 100, and 300 micrograms)
Number of subjects: 15
Study 8856613 — intervention group
Group type: EXPERIMENTAL
Intervention: V beta 17 peptide vaccination (100 micrograms)
Number of subjects: 15
Study 8856613 — intervention group
Group type: EXPERIMENTAL
Intervention: V beta 17 peptide vaccination (300 micrograms)
Number of subjects: 15
Study 8856613 — intervention group
Group type: EXPERIMENTAL
Intervention: V beta 17 peptide vaccination
Number of subjects: 15
Study 1794215 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril monotherapy
Number of subjects: 91
Study 1794215 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril + Hydrochlorothiazide (HCTZ)
Number of subjects: 91
Study 1794215 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol and/or Hydrochlorothiazide (HCTZ)
Number of subjects: 91
Study 1794215 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 91
Study 6363079 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidoflazine
Number of subjects: 24
Study 6363079 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidoflazine and propranolol combination
Number of subjects: 24
Study 6363079 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 24
Study 31791416 — intervention group
Group type: EXPERIMENTAL
Intervention: Tennant Biomodulator
Number of subjects: 100
Study 31791416 — intervention group
Group type: COMPARATOR
Intervention: Traditional Chinese acupuncture
Number of subjects: 100
Study 31791416 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 100
Study 29233196 — intervention group
Group type: EXPERIMENTAL
Intervention: Media Smart-Targeted (MS-T)
Number of subjects: 575
Study 29233196 — intervention group
Group type: EXPERIMENTAL
Intervention: Student Bodies (SB)
Number of subjects: 575
Study 29233196 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 575
Study 27289105 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Number of subjects: 1051
Study 27289105 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular visit with midwife/social worker)
Number of subjects: 1051
Study 27289105 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 1051
Study 23466193 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy massage with essential oil (AT)
Number of subjects: 63
Study 23466193 — intervention group
Group type: EXPERIMENTAL
Intervention: Oil massage without essential oil (OT)
Number of subjects: 63
Study 23466193 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 63
Study 22727431 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive servo ventilation (ASV)
Number of subjects: 22
Study 22727431 — intervention group
Group type: COMPARATOR
Intervention: Non-ASV treatment
Number of subjects: 22
Study 20634298 — intervention group
Group type: EXPERIMENTAL
Intervention: Belatacept
Number of subjects: 102
Study 20634298 — intervention group
Group type: COMPARATOR
Intervention: CsA
Number of subjects: 102
Study 18076864 — intervention group
Group type: EXPERIMENTAL
Intervention: TiF(4) solution applied (ERO+F)
Number of subjects: 10
Study 18076864 — intervention group
Group type: COMPARATOR
Intervention: No treatment (ERO+no-F)
Number of subjects: 10
Study 18076864 — intervention group
Group type: EXPERIMENTAL
Intervention: TiF(4) only (no-ERO+F)
Number of subjects: 10
Study 16004704 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate plus sulfadoxine-pyrimethamine (ASP)
Number of subjects: 60
Study 16004704 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine (SP) alone
Number of subjects: 60
Study 11841884 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil infusion at a rate of 1 mg/min to a maximum of 20 mg
Number of subjects: 161
Study 11841884 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem infusion at a rate of 2.5 mg/min to a maximum of 50 mg
Number of subjects: 161
Study 11841884 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil infusion
Number of subjects: 161
Study 11841884 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem infusion
Number of subjects: 161
Study 9951214 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD-10 hyperkinetic disorder and DSM-IV ADHD (n=21)
Number of subjects: 77
Study 9951214 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD only (n=22)
Number of subjects: 77
Study 9951214 — intervention group
Group type: COMPARATOR
Intervention: Clinic control (n=15)
Number of subjects: 77
Study 9951214 — intervention group
Group type: COMPARATOR
Intervention: Normal control (n=19)
Number of subjects: 77
Study 7772352 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiberoptic bronchoscope with newly developed mask adapter (Group FI)
Number of subjects: 30
Study 7772352 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope (Group L)
Number of subjects: 30
Study 7772352 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal mask airway (Group LMA)
Number of subjects: 30
Study 2286469 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin trometamol (3 g single dose)
Number of subjects: 0
Study 2286469 — intervention group
Group type: COMPARATOR
Intervention: Nitrofurantoin (200 mg per day for one week)
Number of subjects: 0
Study 323118 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 1 g/day
Number of subjects: 4
Study 323118 — intervention group
Group type: COMPARATOR
Intervention: Atropine 2-4 mg/day
Number of subjects: 4
Study 323118 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 1 g/day and Atropine 2-4 mg/day
Number of subjects: 4
Study 323118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 31163975 — intervention group
Group type: EXPERIMENTAL
Intervention: Syndemic factors (e.g., polydrug use, hazardous alcohol consumption, client‐perpetrated violence, depression, and sexually transmitted infections)
Number of subjects: 295
Study 31163975 — intervention group
Group type: EXPERIMENTAL
Intervention: Three syndemic factors
Number of subjects: 295